Brian Cheng
Stock Analyst at JP Morgan
(1.52)
# 3,097
Out of 5,044 analysts
68
Total ratings
46.3%
Success rate
-10.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brian Cheng
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Maintains: Overweight | $20 → $23 | $19.30 | +19.17% | 3 | Oct 16, 2025 | |
| ALLO Allogene Therapeutics | Downgrades: Underweight | n/a | $1.26 | - | 5 | Oct 10, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Underweight | n/a | $1.78 | - | 1 | Oct 10, 2025 | |
| ABSI Absci | Initiates: Overweight | n/a | $4.40 | - | 1 | Oct 2, 2025 | |
| IMVT Immunovant | Maintains: Overweight | $37 → $33 | $21.98 | +50.14% | 4 | Sep 30, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $41 → $47 | $43.71 | +7.53% | 2 | Sep 26, 2025 | |
| ROIV Roivant Sciences | Maintains: Overweight | $16 → $20 | $18.41 | +8.64% | 7 | Sep 18, 2025 | |
| CRSP CRISPR Therapeutics AG | Initiates: Overweight | $70 | $64.17 | +9.09% | 1 | Sep 18, 2025 | |
| PGEN Precigen | Upgrades: Neutral | n/a | $4.06 | - | 3 | Aug 15, 2025 | |
| IMNM Immunome | Maintains: Overweight | $23 → $22 | $16.39 | +34.23% | 3 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $33.87 | - | 1 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $53 → $57 | $78.51 | -27.40% | 5 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $45 → $13 | $13.96 | -6.88% | 4 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $3.17 | - | 3 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $28 | $14.25 | +96.49% | 4 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $39 → $33 | $7.61 | +333.64% | 2 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $6 | $2.63 | +128.14% | 2 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $125 | $10.23 | +1,121.90% | 3 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $14 | $0.74 | +1,802.95% | 3 | Sep 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | n/a | $4.43 | - | 3 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $0.86 | +601.26% | 2 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $2.23 | - | 1 | Dec 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $2.38 | - | 2 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $85 | $9.88 | +760.32% | 2 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $21 | $7.24 | +190.06% | 1 | Aug 3, 2021 |
Zymeworks
Oct 16, 2025
Maintains: Overweight
Price Target: $20 → $23
Current: $19.30
Upside: +19.17%
Allogene Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.26
Upside: -
Pliant Therapeutics
Oct 10, 2025
Downgrades: Underweight
Price Target: n/a
Current: $1.78
Upside: -
Absci
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $4.40
Upside: -
Immunovant
Sep 30, 2025
Maintains: Overweight
Price Target: $37 → $33
Current: $21.98
Upside: +50.14%
CG Oncology
Sep 26, 2025
Maintains: Overweight
Price Target: $41 → $47
Current: $43.71
Upside: +7.53%
Roivant Sciences
Sep 18, 2025
Maintains: Overweight
Price Target: $16 → $20
Current: $18.41
Upside: +8.64%
CRISPR Therapeutics AG
Sep 18, 2025
Initiates: Overweight
Price Target: $70
Current: $64.17
Upside: +9.09%
Precigen
Aug 15, 2025
Upgrades: Neutral
Price Target: n/a
Current: $4.06
Upside: -
Immunome
Aug 7, 2025
Maintains: Overweight
Price Target: $23 → $22
Current: $16.39
Upside: +34.23%
Mar 27, 2025
Initiates: Overweight
Price Target: n/a
Current: $33.87
Upside: -
Mar 4, 2025
Maintains: Overweight
Price Target: $53 → $57
Current: $78.51
Upside: -27.40%
Feb 28, 2025
Downgrades: Neutral
Price Target: $45 → $13
Current: $13.96
Upside: -6.88%
Dec 16, 2024
Downgrades: Underweight
Price Target: n/a
Current: $3.17
Upside: -
Nov 7, 2024
Maintains: Overweight
Price Target: $27 → $28
Current: $14.25
Upside: +96.49%
Jul 31, 2024
Maintains: Overweight
Price Target: $39 → $33
Current: $7.61
Upside: +333.64%
May 2, 2024
Downgrades: Neutral
Price Target: $16 → $6
Current: $2.63
Upside: +128.14%
Mar 19, 2024
Upgrades: Neutral
Price Target: $125
Current: $10.23
Upside: +1,121.90%
Sep 25, 2023
Maintains: Overweight
Price Target: $17 → $14
Current: $0.74
Upside: +1,802.95%
Aug 10, 2023
Upgrades: Neutral
Price Target: n/a
Current: $4.43
Upside: -
Jun 1, 2023
Downgrades: Neutral
Price Target: $20 → $6
Current: $0.86
Upside: +601.26%
Dec 16, 2022
Initiates: Neutral
Price Target: n/a
Current: $2.23
Upside: -
Dec 7, 2022
Downgrades: Underweight
Price Target: n/a
Current: $2.38
Upside: -
Aug 10, 2021
Maintains: Overweight
Price Target: $71 → $85
Current: $9.88
Upside: +760.32%
Aug 3, 2021
Initiates: Overweight
Price Target: $21
Current: $7.24
Upside: +190.06%